Tyrosine kinase inhibitor + Monoclonal antibodyPhase 3 trialInvestigational
regorafenib + bevacizumab
How it works
Blocks multiple enzymes involved in cancer cell growth and angiogenesis, starving them of nutrients and oxygen, and blocks the formation of new blood vessels that feed cancer cells.
Cancer types
Colorectal Cancer— All patients
Efficacy
In clinical trials, the combination of Regorafenib and Bevacizumab improved overall survival in patients with metastatic colorectal cancer.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.